According to the associated press, gunshots rang out near the government building in Kiev, Ukraine.

China's First Oral COVID-19 Antiviral Medicine in Dispute

An obscure Chinese company called Genuine Biotech(Chinese: 真实生物) was suddenly put under the spotlight on July 25 when the Chinese authority announced the conditional approval of the company's application for adding the treatment of COVID-19 as a new indication of Azvudine under the special review and approval procedures for drug registration.

China's First Outbound Investment Regulation Takes Effect, Creating a Unified Rulebook for 50,000 Overseas Enterprises

China's State Council regulation on outbound investment came into force on July 1, 2026, establishing for the first time a single administrative-rule framework to govern the more than 50,000 Chinese enterprises that operate outside the country.

Midea's PortaSplit AC Doubles Europe Shipments to Over 200,000 Units as Heatwaves Turn Chinese Portable Cooling into an Emergency Essential

Midea Group (美的集团) has shipped more than 200,000 units of its PortaSplit portable split air conditioner to Europe this year, doubling year-on-year volumes, as the Chinese home appliance maker rides a structural demand surge in a continent where residential AC penetration sits at just 3% to 6%.

EqualOcean Releases 2026 GoGlobal FinTech Service Enablers Top 10 at GGF2026

SHANGHAI, June 11, 2026 — EqualOcean, a leading research and intelligence platform focused on Chinese companies’ global expansion, officially released its 2026 GoGlobal FinTech Service Enablers Top 10 during the GoGlobal Forum of 100 2026 (GGF2026), one of China’s leading annual forums dedicated to globalization and international business expansion.

Junshi Biosciences Receives NMPA Approval of sNDA for Toripalimab

The study data showed that compared to chemotherapy alone, toripalimab in combination with chemotherapy in the first-line treatment of patients with advanced NSCLC without EGFR/ALK mutations could significantly improve the PFS and the OS of patients with a manageable safety profile regardless of PD-L1 expression status.